GLYXAMBI 25MG/5MG 30 TAB IMPORTED
- Home
- Shop
- oral medication
- GLYXAMBI 25MG/5MG 30 TAB IMPORTED

GLYXAMBI 25MG/5MG 30 TAB IMPORTED
0 out of 5
EGP 700.00
GLYXAMBI 25MG/5MG 30 TAB IMPORTED
Glyxambi 25 mg/5 mg (Empagliflozin/Linagliptin) 30 Tablets is a combination oral medication used to manage type 2 diabetes. It combines an SGLT2 inhibitor (empagliflozin) and a DPP-4 inhibitor (linagliptin) to help control blood sugar levels.
💊 Product Overview
-
Brand Name: Glyxambi
-
Active Ingredients: Empagliflozin 25 mg + Linagliptin 5 mg
-
Form: Film-coated tablets
-
Pack Size: 30 tablets
-
Manufacturer: Boehringer Ingelheim
International Code: 4048846023889
Availability: In stock
SKU: 89882
EAN: 4048846023889
Category: oral medication
Tag: manage type 2 diabetes
Brand: GLYXAMBI
- Description
- Additional information
Description
GLYXAMBI 25MG/5MG 30 TAB IMPORTED
Thank you for reading this post, don't forget to subscribe!Glyxambi 25 mg/5 mg (Empagliflozin/Linagliptin) 30 Tablets is a combination oral medication used to manage type 2 diabetes. It combines an SGLT2 inhibitor (empagliflozin) and a DPP-4 inhibitor (linagliptin) to help control blood sugar levels.
💊 Product Overview
-
Brand Name: Glyxambi
-
Active Ingredients: Empagliflozin 25 mg + Linagliptin 5 mg
-
Form: Film-coated tablets
-
Pack Size: 30 tablets
-
Manufacturer: Boehringer Ingelheim
-
⚠️ Important Usage Notes
-
Dosage: Typically, one tablet is taken orally once daily, as prescribed by your healthcare provider.
-
Not Recommended For:
-
Individuals with type 1 diabetes
-
Those with a history of diabetic ketoacidosis
-
Patients with severe kidney impairment
-
Pregnant or breastfeeding women
-
-
Common Side Effects:
-
Urinary tract infections
-
Upper respiratory tract infections
-
Nasopharyngitis
-
Headache
-
Always consult with your healthcare provider before starting any new medication.
-
Additional information
Brand | |
---|---|
Size | 30TAb |
Related Products
-
-
oral medication
INHALEX 18mcg +with handihaler device 30CAP*
0 out of 5There is no AI review summary. -